Maculus Therapeutix welcomes Privity, Prepares Capital Raise for Novel Drug Delivery Platform
SANTA CLARA, CA & DUBAI, Feb 19, 2021 – (ACN Newswire) – Maculus Therapeutix, a preclinical-stage biopharmaceutical company that has developed a SINGLE injection platform to treat wet AMD (Age-related Macular Degeneration) and DME (Diabetic Macular Edema) instead of the standard 8-12 monthly injections, is pleased to welcome Privity FZ LLE as a partner and... » read more
